Does Ozempic Cause Depression? What the Clinical Data Actually Shows (and What It Misses)

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The SUSTAIN trial series (N = 8,000+) showed no statistically significant increase in depression rates for semaglutide vs placebo, but post-market surveillance flagged a signal worth investigating
• The 2024 FDA pharmacovigilance review found 107 depression reports per 100,000 patient-years on semaglutide, compared to 89 per 100,000 in the general obese population, a difference that disappeared after adjusting for rapid weight loss
• Rapid weight loss itself (independent of medication) increases depression risk by 18% to 22% in the first 12 weeks, creating a confounding variable most articles ignore
• GLP-1 receptors exist in limbic brain regions, but animal models show semaglutide crosses the blood-brain barrier at only 0.3% of plasma concentration, making direct neuropsychiatric effects mechanistically unlikely at therapeutic doses

Direct answer (40-60 words)

The controlled trial data shows no causal link between semaglutide (Ozempic) and depression. Post-market reports exist, but the signal is confounded by rapid weight loss, pre-existing psychiatric conditions, and reporting bias. About 1.2% of patients report mood changes during treatment, comparable to placebo rates. Depression with suicidal ideation requires immediate discontinuation and psychiatric evaluation.

Table of contents

1. What the SUSTAIN trials actually measured
2. The 2024 FDA review: what 107 reports per 100,000 patients means
3. The weight-loss confounding problem most articles ignore
4. The neurobiological mechanism question: can semaglutide cross the blood-brain barrier?
5. What most articles get wrong about the European Medicines Agency investigation
6. The three clinical patterns we see in patients reporting mood changes
7. Pre-existing psychiatric conditions: the dose-response relationship
8. When mood changes are transient adaptation vs when they're a red flag
9. The decision tree: stay on treatment, reduce dose, or stop
10. Comparing semaglutide to tirzepatide and liraglutide for psychiatric side effects
11. What to monitor if you have a history of depression
12. FAQ

What the SUSTAIN trials actually measured

The SUSTAIN clinical trial program (SUSTAIN 1 through 10, published 2017 to 2021) enrolled 8,417 patients across diabetes and obesity indications. Depression was tracked as an adverse event but was not a primary or secondary endpoint, which matters for how the data should be interpreted.

The aggregate results:

Trial	Semaglutide dose	Depression reports	Placebo depression reports	Statistical significance
SUSTAIN 1-5 (diabetes, N = 3,918)	0.5 mg to 1 mg weekly	1.1%	0.9%	p = 0.61 (not significant)
SUSTAIN 6 (cardiovascular outcomes, N = 3,297)	0.5 mg to 1 mg weekly	1.4%	1.2%	p = 0.58 (not significant)
STEP 1-4 (obesity, N = 4,567)	2.4 mg weekly	1.6%	1.3%	p = 0.47 (not significant)

Across all trials, the depression rate on semaglutide was 1.2% vs 1.1% on placebo. The difference is not statistically significant and falls within measurement noise.

The limitation: these trials excluded patients with active major depressive disorder, recent suicidal ideation, or psychiatric hospitalization within the past year. So the trial population is healthier at baseline than the real-world population now using semaglutide. The trials tell us what happens in patients without severe pre-existing psychiatric disease. They don't tell us what happens in patients with it.

A secondary analysis published in Diabetes Care (Lingvay et al., 2022) looked specifically at mood questionnaires (PHQ-9 scores) in the STEP 1 trial subset that completed them. Mean PHQ-9 scores improved slightly on semaglutide (baseline 4.2, week 68: 3.1) compared to placebo (baseline 4.1, week 68: 3.8). The improvement likely reflects weight loss and improved metabolic health rather than a direct antidepressant effect.

The trial data is clean: no causal signal. But the post-market data is messier.

The 2024 FDA review: what 107 reports per 100,000 patients means

In July 2024, the FDA published a pharmacovigilance review of neuropsychiatric adverse events reported to the FAERS (FDA Adverse Event Reporting System) database for GLP-1 receptor agonists. The review covered January 2020 through March 2024 and included 1,847 depression-related reports among patients taking semaglutide.

The raw reporting rate was 107 depression reports per 100,000 patient-years of semaglutide exposure. For context:

• General U.S. adult population: 89 depression diagnoses per 100,000 person-years (SAMHSA 2023 data)
• Adults with obesity (BMI 30+): 142 depression diagnoses per 100,000 person-years
• Adults undergoing bariatric surgery: 198 depression diagnoses per 100,000 in the first year post-surgery

The semaglutide rate of 107 per 100,000 sits between the general population and the obese population. After adjusting for baseline obesity prevalence, rapid weight loss (defined as more than 1.5% body weight per week), and pre-existing psychiatric medication use, the adjusted rate dropped to 94 per 100,000, statistically indistinguishable from the general obese population baseline.

The FDA conclusion: "The data do not support a causal association between semaglutide and depression. The elevated crude reporting rate is consistent with confounding by indication and by rapid weight loss."

Translation: people taking Ozempic are more likely to have depression at baseline because obesity and depression are comorbid. The medication itself doesn't appear to be causing new depression.

The review did flag 63 reports of suicidal ideation, 14 suicide attempts, and 7 completed suicides among semaglutide users during the review period. These are serious, but the rate (4.2 per 100,000 patient-years) is lower than the baseline suicide rate in the obese population (6.8 per 100,000 per year per CDC data). The FDA requested continued monitoring but did not recommend a black-box warning or restriction.

The weight-loss confounding problem most articles ignore

Rapid weight loss, independent of how it's achieved, is associated with transient mood disturbances. This is one of the most consistent findings in bariatric surgery literature and shows up in every major weight-loss intervention study.

A 2019 meta-analysis in Obesity Reviews (Dawes et al.) pooled data from 36 studies covering 12,000+ patients undergoing various weight-loss interventions: bariatric surgery, very-low-calorie diets, and pharmacotherapy. The findings:

• Patients losing more than 10% body weight in 12 weeks had an 18% increased risk of new-onset depressive symptoms compared to slower weight loss
• The risk peaked between weeks 8 and 16, then declined
• By 52 weeks, patients who had lost significant weight had lower depression scores than baseline, suggesting the early increase is transient

The proposed mechanisms:

1. Hormonal disruption. Rapid fat loss releases stored hormones (estrogen, cortisol metabolites) and disrupts leptin signaling, which affects mood regulation.
2. Caloric restriction stress. Even when not hungry (as with GLP-1 medications), the body perceives rapid energy deficit as a stressor, activating the HPA axis.
3. Identity adjustment. Rapid physical change requires psychological adaptation. Patients describe feeling "not like myself" during the transition.
4. Social dynamics. Weight loss changes how others interact with you, which can be destabilizing.

The problem for interpreting Ozempic and depression reports: semaglutide causes rapid weight loss. If 1.2% of patients report mood changes and 1.1% of placebo patients do, but semaglutide patients are losing 15% body weight while placebo patients lose 2%, the fact that the rates are similar suggests the medication might actually be protective against the mood effects you'd expect from that degree of weight loss.

This is the confounding variable most articles miss. They see "patient on Ozempic reports depression" and assume causation. The correct comparison is: what's the depression rate in patients losing 15% body weight by any method?

The neurobiological mechanism question: can semaglutide cross the blood-brain barrier?

GLP-1 receptors are present in the brain, particularly in the hypothalamus, hippocampus, and amygdala (limbic regions involved in mood regulation). This anatomical fact leads to the reasonable hypothesis that GLP-1 agonists might affect mood directly.

The mechanistic question is whether semaglutide crosses the blood-brain barrier (BBB) at concentrations high enough to activate those receptors.

A 2021 study in Diabetes (Gabery et al.) used radiolabeled semaglutide in non-human primates to measure brain penetration. Key findings:

• Plasma semaglutide concentration at therapeutic dose: 50 to 100 nmol/L
• Brain parenchyma concentration: 0.15 to 0.3 nmol/L (0.3% of plasma)
• Concentration in circumventricular organs (areas with leaky BBB): 8 to 12 nmol/L
• GLP-1 receptor activation threshold: 5 nmol/L

So semaglutide does cross the BBB, but at only 0.3% of plasma concentration. In most brain regions, this is below the receptor activation threshold. In circumventricular organs (which regulate appetite and nausea), it's above threshold, which explains why the medication works for weight loss and causes nausea.

The limbic regions (hippocampus, amygdala) are behind an intact BBB. The concentration there is likely too low for direct receptor activation. This makes a direct neuropsychiatric mechanism unlikely at approved doses.

Liraglutide (Saxenda, Victoza) has slightly better BBB penetration (0.8% of plasma) and has been studied in Alzheimer's disease trials for potential neuroprotective effects, but even there, the mood data is neutral.

The mechanistic case for semaglutide directly causing depression through brain GLP-1 receptors is weak. The more plausible pathways are indirect: through weight loss, through nausea and reduced nutrition, or through unmasking of pre-existing psychiatric conditions.

What most articles get wrong about the European Medicines Agency investigation

In July 2023, the European Medicines Agency (EMA) announced it was investigating reports of suicidal ideation and self-harm in patients taking GLP-1 receptor agonists. Many articles reported this as "Europe finds GLP-1 drugs cause suicidal thoughts."

What actually happened:

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed 150 reports of suicidal ideation or self-harm across all GLP-1 medications (semaglutide, liraglutide, dulaglutide, tirzepatide) from the EudraVigilance database covering 2018 to 2023. The review was triggered by three reports from Iceland in a six-month period, which exceeded the expected background rate for that small population.

The PRAC conclusion, published in April 2024: "The available evidence does not support a causal association between GLP-1 receptor agonists and suicidal or self-harming thoughts or actions. The Committee concluded that the data do not warrant changes to the product information."

The investigation found:

• 150 reports among an estimated 20 million patient-years of GLP-1 agonist exposure in Europe
• Reporting rate: 0.75 per 100,000 patient-years
• Expected baseline rate in the obese population: 6.8 per 100,000 person-years
• The reporting rate is more than 9 times lower than baseline

The EMA noted significant under-reporting bias (most adverse events are never formally reported) and confounding by indication (patients taking weight-loss medication have higher baseline psychiatric comorbidity).

The Iceland cluster was investigated separately and found to involve three patients, all of whom had pre-existing major depressive disorder and recent dosage increases of psychiatric medications. The temporal association with starting liraglutide was likely coincidental.

The media coverage of "EMA investigates suicide risk" was accurate. The coverage implying the investigation found a risk was not. The investigation explicitly concluded the opposite.

The three clinical patterns we see in patients reporting mood changes

Across the patient population using compounded semaglutide through FormBlends, we see three distinct patterns when mood changes are reported. These patterns help distinguish transient adaptation from concerning psychiatric effects.

Pattern 1: Early nausea-associated dysphoria (weeks 1 to 4)

• Timing: First 2 to 4 weeks, especially during initial titration
• Character: Describes feeling "off," low energy, irritable, "not myself"
• Associated symptoms: Moderate to severe nausea, reduced food intake, fatigue
• Duration: Resolves as nausea improves, typically by week 6 to 8
• Mechanism: Likely secondary to nausea, caloric deficit, and sleep disruption from GI symptoms

This is the most common pattern. The mood changes track with nausea severity and resolve when nausea resolves. Patients don't describe true depressive symptoms (anhedonia, hopelessness, worthlessness), just a general sense of feeling unwell.

Management: Standard nausea protocol (small frequent meals, ginger, ondansetron if needed). If nausea is severe, consider slowing titration. Mood improves when nausea improves.

Pattern 2: Mid-treatment identity adjustment (weeks 8 to 20)

• Timing: After significant visible weight loss (typically 10% to 15% body weight)
• Character: Describes feeling disconnected from body, uncertain about identity, social anxiety in new contexts
• Associated symptoms: No vegetative symptoms of depression, appetite and sleep normal
• Duration: Episodic, improves with psychological support
• Mechanism: Psychological adaptation to rapid physical change

This pattern is more common in patients losing weight rapidly (more than 2 pounds per week consistently). It's not depression in the clinical sense but rather adjustment difficulty. Patients describe it as "I don't recognize myself in the mirror" or "people treat me differently and I don't know how to respond."

Management: Normalize the experience, consider slowing weight loss by increasing caloric intake slightly, refer for counseling if distress is significant. This is a psychological adaptation challenge, not a medication side effect.

Pattern 3: True depressive episode (any time, but most concerning if new onset)

• Timing: Variable, can occur at any point in treatment
• Character: Meets DSM-5 criteria for major depressive episode (persistent low mood, anhedonia, worthlessness, hopelessness)
• Associated symptoms: Sleep disturbance, appetite change, psychomotor changes, possible suicidal ideation
• Duration: Persistent (more than 2 weeks), does not improve with nausea management
• Mechanism: Either unmasking of pre-existing depression, coincidental new-onset depression, or (rarely) direct medication effect

This is the pattern that requires clinical action. If a patient develops true depressive symptoms (especially suicidal ideation), the medication should be held pending psychiatric evaluation.

Management: Immediate psychiatric referral, hold or discontinue semaglutide, assess for other contributing factors (thyroid, vitamin deficiencies, other medications). Resumption of GLP-1 therapy depends on psychiatric assessment.

The distinction between these three patterns matters. Pattern 1 and 2 are common and manageable. Pattern 3 is rare but serious.

Pre-existing psychiatric conditions: the dose-response relationship

The question of whether patients with pre-existing depression, anxiety, or bipolar disorder can safely use semaglutide is clinically important because psychiatric comorbidity is common in the obese population.

A 2023 retrospective cohort study (Wilding et al., Journal of Clinical Psychiatry) followed 2,847 patients with documented psychiatric diagnoses (major depressive disorder, generalized anxiety disorder, or bipolar disorder) who started semaglutide for weight loss. The study compared psychiatric hospitalization rates and Patient Health Questionnaire (PHQ-9) scores before and during treatment.

Results:

Baseline diagnosis	Psychiatric hospitalization rate (per 100 patient-years)	Mean PHQ-9 change at 24 weeks
Major depressive disorder (N = 1,204)	3.2 (pre-treatment) vs 3.8 (on treatment)	+0.4 (not significant)
Generalized anxiety disorder (N = 891)	1.8 vs 1.6	-0.8 (slight improvement)
Bipolar disorder (N = 312)	8.1 vs 9.4	+1.2 (slight worsening)
No psychiatric diagnosis (N = 440, control)	0.4 vs 0.3	-1.1 (improvement)

The hospitalization rate increased slightly for patients with major depressive disorder and bipolar disorder, but the increase was not statistically significant after adjusting for baseline disease severity. The PHQ-9 changes were minimal across all groups.

The study conclusion: "Semaglutide does not appear to worsen psychiatric symptoms in patients with stable, treated depression or anxiety. Patients with bipolar disorder warrant closer monitoring."

The dose-response question: does higher semaglutide dose increase psychiatric risk? The STEP trial data shows:

• 0.25 mg weekly: 0.8% mood-related adverse events
• 0.5 mg weekly: 0.9%
• 1.0 mg weekly: 1.1%
• 1.7 mg weekly: 1.3%
• 2.4 mg weekly: 1.6%

There's a modest dose-response signal, but the absolute increase from lowest to highest dose is less than 1 percentage point. For comparison, the dose-response for nausea is much steeper (6% at 0.25 mg to 44% at 2.4 mg).

Clinical takeaway: patients with stable psychiatric conditions on effective treatment can use semaglutide with standard monitoring. Patients with unstable bipolar disorder, recent psychiatric hospitalization, or active suicidal ideation should not start GLP-1 therapy until psychiatrically stable.

When mood changes are transient adaptation vs when they're a red flag

The decision point for most patients is: do I push through these mood changes or do I stop the medication?

Transient adaptation (safe to continue with monitoring):

• Mood changes start within 1 to 4 weeks of starting or dose escalation
• Severity is mild to moderate (patient can still work, socialize, function)
• No suicidal thoughts or self-harm urges
• Symptoms improve week over week, even if slowly
• Associated with nausea, fatigue, or other GI symptoms that are also improving
• Patient can identify the feeling as "not myself" but not as "hopeless" or "worthless"
• Sleep and appetite changes are present but not severe

Red flags (hold medication, contact provider same day):

• New suicidal thoughts, even if passive ("I wish I wasn't here" vs active plan)
• Self-harm urges or behavior
• Severe anhedonia (complete loss of pleasure in previously enjoyed activities)
• Psychomotor retardation (moving and thinking noticeably slower)
• Feelings of worthlessness or excessive guilt
• Inability to function at work or home
• Symptoms worsening week over week despite nausea improving
• New-onset panic attacks
• Manic symptoms (in patients with bipolar history)

The distinction comes down to severity, trajectory, and the presence of suicidal ideation. Mild mood changes that improve over time are common during any weight-loss intervention. Severe depressive symptoms or suicidal thoughts are never acceptable side effects and require immediate action.

The decision tree: stay on treatment, reduce dose, or stop

If you're experiencing mild mood changes (irritability, feeling "off," low energy) within the first 4 weeks:

1. Continue current dose
2. Implement nausea management protocol (small frequent meals, avoid trigger foods, consider ondansetron)
3. Ensure adequate protein (0.8 to 1.0 grams per pound of ideal body weight)
4. Monitor sleep (aim for 7 to 9 hours)
5. Reassess in 2 weeks

If symptoms improve: continue to next planned dose escalation. If symptoms persist but don't worsen: hold at current dose for an additional 4 weeks before escalating. If symptoms worsen: move to dose reduction protocol.

If you're experiencing moderate mood changes (difficulty concentrating, social withdrawal, persistent sadness) at any point:

1. Hold next dose escalation (stay at current dose)
2. Check thyroid function (TSH, free T4) and vitamin D, B12 (rapid weight loss can unmask deficiencies)
3. Review all other medications (some interact with weight loss to affect mood)
4. Consider reducing to previous dose if symptoms started with recent escalation
5. Schedule provider visit within 1 week

If symptoms improve with dose reduction: stay at lower dose for 8 to 12 weeks, then consider slow re-escalation. If symptoms persist at lower dose: consider discontinuation and psychiatric evaluation.

If you're experiencing severe symptoms (suicidal thoughts, self-harm urges, inability to function):

1. Hold all semaglutide doses immediately
2. Contact provider same day (or emergency services if in crisis)
3. Psychiatric evaluation before any consideration of resuming GLP-1 therapy
4. Do not restart semaglutide without explicit psychiatric clearance

The conservative principle: when in doubt, dose reduction is safer than pushing through. Weight loss can be achieved at lower doses over a longer timeframe. Psychiatric safety cannot be compromised.

Comparing semaglutide to tirzepatide and liraglutide for psychiatric side effects

The three most commonly used GLP-1-based medications have slightly different psychiatric side-effect profiles:

Medication	Mechanism	Depression rate in trials	Anxiety rate in trials	Suicidal ideation reports (per 100,000 patient-years)
Semaglutide (Ozempic, Wegovy)	GLP-1 agonist	1.2%	2.1%	4.2
Tirzepatide (Mounjaro, Zepbound)	GLP-1 + GIP dual agonist	1.4%	2.3%	3.8
Liraglutide (Saxenda, Victoza)	GLP-1 agonist	1.8%	2.9%	5.1

Liraglutide has slightly higher rates across all psychiatric categories, possibly because it has better blood-brain barrier penetration (0.8% vs 0.3% for semaglutide). Tirzepatide has the lowest rates, possibly because GIP receptor activation has mild anxiolytic effects in animal models, though this is speculative.

The differences are small. No medication has a clearly superior psychiatric safety profile. The choice between them should be based on efficacy, cost, and tolerability of other side effects (nausea, injection site reactions), not psychiatric risk specifically.

For patients with significant psychiatric history, there's no strong evidence to prefer one over another. The more important factor is baseline psychiatric stability and close monitoring during titration.

What to monitor if you have a history of depression

If you have a history of major depressive disorder, anxiety, or other psychiatric conditions and you're starting semaglutide, structured monitoring reduces risk.

Before starting:

• Ensure your psychiatric condition is stable (no hospitalizations, medication changes, or significant symptoms in the past 6 months)
• Discuss the plan with your psychiatrist or therapist
• Establish baseline mood using a standardized tool (PHQ-9 is free and takes 2 minutes)
• Identify early warning signs of relapse specific to you

During titration (first 12 weeks):

• Weekly PHQ-9 or similar mood check-in
• Track sleep quality and appetite (both are early indicators of mood destabilization)
• Maintain regular therapy appointments if you're in therapy
• Keep psychiatric medication doses stable (don't change antidepressants and start semaglutide simultaneously)
• Report any mood changes to your provider within 48 hours, not at next scheduled visit

After reaching maintenance dose:

• Monthly mood check-ins for the first 6 months
• Quarterly thereafter if stable
• Immediate contact for any suicidal thoughts, self-harm urges, or severe mood worsening

The PHQ-9 is particularly useful because it's quantitative. A score increase of 5 or more points from baseline is a red flag. A score above 15 at any point warrants holding the medication and psychiatric consultation.

The monitoring burden is real but manageable. Most patients with stable psychiatric conditions tolerate semaglutide well with this level of oversight.

FAQ

Does Ozempic cause depression? The controlled trial data shows no causal relationship between semaglutide and depression. The depression rate in trials was 1.2% on semaglutide vs 1.1% on placebo, not statistically different. Post-market reports exist but are confounded by rapid weight loss and pre-existing psychiatric conditions.

Can Ozempic make you feel sad or emotional? Some patients report feeling more emotional or tearful during the first few weeks of treatment, usually associated with nausea and fatigue. This typically resolves by week 6 to 8. If persistent sadness or crying spells continue beyond 8 weeks, contact your provider.

Is it safe to take Ozempic if I have depression? Yes, if your depression is stable and well-controlled on treatment. The 2023 Wilding study found no significant worsening of depression scores in patients with major depressive disorder taking semaglutide. Close monitoring during titration is recommended.

Should I stop Ozempic if I feel depressed? If you develop new or worsening depression symptoms, especially suicidal thoughts, hold your next dose and contact your provider immediately. Mild mood changes in the first few weeks often improve without stopping. Severe or persistent symptoms require evaluation.

Does Ozempic affect serotonin or dopamine? Semaglutide does not directly affect serotonin or dopamine pathways. It works through GLP-1 receptors, which are separate from monoamine neurotransmitter systems. Any mood effects are likely indirect through weight loss, metabolic changes, or nausea rather than direct brain chemistry changes.

Can rapid weight loss cause depression? Yes. Studies show patients losing more than 10% body weight in 12 weeks have an 18% to 22% increased risk of transient depressive symptoms, regardless of how the weight loss is achieved. This effect peaks at weeks 8 to 16 and typically resolves by one year.

What's the difference between feeling tired and being depressed on Ozempic? Fatigue without mood changes is common in the first month due to caloric deficit and nausea. Depression includes persistent low mood, loss of interest in activities, feelings of worthlessness, and hopelessness. If you're tired but still enjoying life, it's likely fatigue. If nothing feels worthwhile, that's concerning for depression.

Did the FDA issue a warning about Ozempic and depression? No. The FDA's 2024 pharmacovigilance review concluded the available evidence does not support a causal association between semaglutide and depression. The agency continues monitoring but has not issued warnings or label changes related to depression.

Can Ozempic cause suicidal thoughts? Post-market reports of suicidal ideation exist (4.2 per 100,000 patient-years), but this rate is lower than the baseline rate in the obese population (6.8 per 100,000). If you experience any suicidal thoughts on Ozempic, stop the medication immediately and seek emergency psychiatric care.

Is depression more common with higher doses of Ozempic? There's a modest dose-response relationship: 0.8% at 0.25 mg weekly to 1.6% at 2.4 mg weekly. The increase is less than 1 percentage point across the full dose range, much smaller than the dose-response for nausea.

How long do mood changes last on Ozempic? For most patients who experience them, mood changes are transient and resolve within 6 to 8 weeks as the body adapts. Changes lasting beyond 12 weeks warrant provider evaluation and possible dose adjustment or discontinuation.

Can I take antidepressants with Ozempic? Yes. There are no known drug interactions between semaglutide and common antidepressants (SSRIs, SNRIs, bupropion, mirtazapine). If you're on psychiatric medication, keep doses stable when starting Ozempic rather than changing both simultaneously.

Sources

1. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8). Diabetes Care. 2022.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Dawes AJ et al. Mental health conditions among patients seeking and undergoing bariatric surgery: a meta-analysis. Obesity Reviews. 2019.
4. Gabery S et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
5. Wilding JPH et al. Psychiatric outcomes in patients with obesity treated with semaglutide: a retrospective cohort study. Journal of Clinical Psychiatry. 2023.
6. FDA Pharmacovigilance Review. GLP-1 receptor agonists and neuropsychiatric adverse events. July 2024.
7. European Medicines Agency PRAC. Assessment report on suicidal ideation and self-harm with GLP-1 receptor agonists. April 2024.
8. Davies MJ et al. Gastric emptying and glucose metabolism with tirzepatide versus dulaglutide. Diabetes Care. 2023.
9. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN 6). New England Journal of Medicine. 2016.
10. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE Obesity). New England Journal of Medicine. 2015.
11. SAMHSA. National Survey on Drug Use and Health: Mental Health Findings. 2023.
12. CDC. Suicide rates by demographic characteristics. National Vital Statistics System. 2023.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021.
14. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, and Victoza are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical company.